Who We Are
The Division of Clinical Outcome Assessment (DCOA) comprises multidisciplinary measurement experts and is located in the Office of Drug Evaluation Science (ODES) in the Office of New Drugs (OND), in FDA’s Center for Drug Evaluation and Research (CDER). To support CDER’s mission for patient-focused drug development, we provide leadership, expertise, and advice to promote the use of patient-focused outcome assessment.
What We Do
- Play a central role in promoting innovative, science-based review of COA development, validation, interpretation and communication of COA endpoints throughout the drug development life-cycle.
- Engage with internal and external stakeholders to advance good scientific COA standards and policy development.
- Address unmet medical needs by managing and leading the CDER COA Qualification Program.
Resources for You